Suppr超能文献

临床医生对接受阿片类药物依赖治疗的患者使用大麻及大麻治疗的看法。

Clinicians' Perspectives on Cannabis Use and Cannabis Treatment in Clients Undertaking Opioid Dependence Treatment.

作者信息

Parvaresh Laila, Mills Llewellyn, Gholami Jaleh, Jansen Louisa, Jamshidi Nazila, Baker Kate, Tremonti Christopher, Tracy Marguerite, Dunlop Adrian, Lintzeris Nicholas

机构信息

Drug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, Australia.

Discipline of Addiction Medicine, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.

出版信息

Drug Alcohol Rev. 2025 Jul;44(5):1339-1350. doi: 10.1111/dar.14074. Epub 2025 May 5.

Abstract

INTRODUCTION

There are no prior studies investigating the perspectives of Opioid Treatment Program (OTP) clinicians on clients' cannabis use. This study examines the perspectives of OTP clinicians on patterns of cannabis use; harms and benefits; current and potential interventions and their confidence in implementing them.

METHODS

Clinicians from six public OTP services in New South Wales completed the survey. Participants included nurses, doctors, pharmacists, allied health and consumer workers. Single-level regression models were used to estimate participants' sex, role and experience effect.

RESULTS

A total of 162 participants responded to the survey (estimated response rate 56%). Participants estimated 56.1% (±23.9) of OTP clients had used cannabis in the past month, and 44.9% (±6.5) had cannabis dependence. Clinicians indicated (15.3% ± 17.2%) clients identified problematic cannabis use and (10.7% ± 16.9) sought treatment in the past year. The harms most frequently identified by staff were cannabis dependence (46.5% ± 27.9%), financial issues (37.5% ± 29.2%) and increased tobacco use (33.1% ± 28.2%). The benefits most frequently identified were management of sleep problems (49.7% ± 27.8%), chronic pain symptoms (35.6% ± 24.3%) and improvements in mental health (48.3% ± 25.6%). Sixty-five participants (63.7%) advocated for enhancing efforts to address cannabis use, with none supporting scaling down services. Clinicians prioritised withdrawal services (81%), harm reduction (77.4%), counselling (74%) and medicinal cannabis (59.8%), although the majority had low confidence in delivering most of these interventions.

DISCUSSION AND CONCLUSIONS

Despite awareness about cannabis use patterns and identification of both harms and benefits, clinicians identified low rates of cannabis interventions and low levels of confidence in delivering interventions.

摘要

引言

此前尚无研究调查阿片类药物治疗项目(OTP)临床医生对客户使用大麻情况的看法。本研究考察了OTP临床医生对大麻使用模式、危害与益处、当前及潜在干预措施以及他们对实施这些措施的信心。

方法

新南威尔士州六个公共OTP服务机构的临床医生完成了该调查。参与者包括护士、医生、药剂师、专职医疗人员和消费者工作者。采用单水平回归模型来估计参与者的性别、角色和经验效应。

结果

共有162名参与者回复了调查(估计回复率为56%)。参与者估计,在过去一个月中,56.1%(±23.9)的OTP客户使用过大麻,44.9%(±6.5)的客户有大麻依赖。临床医生指出,在过去一年中,(15.3%±17.2%)的客户存在问题性大麻使用情况,(10.7%±16.9)的客户寻求过治疗。工作人员最常指出的危害是大麻依赖(46.5%±27.9%)、财务问题(37.5%±29.2%)和吸烟增加(33.1%±28.2%)。最常指出的益处是睡眠问题的管理(49.7%±27.8%)、慢性疼痛症状(35.6%±24.3%)和心理健康改善(48.3%±25.6%)。65名参与者(63.7%)主张加大力度解决大麻使用问题,无人支持缩减服务。临床医生将戒断服务(81%)、减少危害(77.4%)、咨询(74%)和药用大麻(59.8%)列为优先事项,不过大多数人对提供这些干预措施的信心较低。

讨论与结论

尽管了解大麻使用模式并认识到其危害和益处,但临床医生发现大麻干预措施的实施率较低,且对提供干预措施的信心不足。

相似文献

1
临床医生对接受阿片类药物依赖治疗的患者使用大麻及大麻治疗的看法。
Drug Alcohol Rev. 2025 Jul;44(5):1339-1350. doi: 10.1111/dar.14074. Epub 2025 May 5.
2
针对大麻使用障碍的心理社会干预措施。
Cochrane Database Syst Rev. 2016 May 5;2016(5):CD005336. doi: 10.1002/14651858.CD005336.pub4.
4
州许可的专业物质使用治疗计划中使用丁丙诺啡的障碍和促进因素:对项目领导层的调查。
J Subst Use Addict Treat. 2024 Jul;162:209351. doi: 10.1016/j.josat.2024.209351. Epub 2024 Mar 17.
5
心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
6
性虐待和暴力的心理社会干预的幸存者、家庭和专业人员的经验:定性证据综合。
Cochrane Database Syst Rev. 2022 Oct 4;10(10):CD013648. doi: 10.1002/14651858.CD013648.pub2.
8
减少持续吸烟危害的干预措施。
Cochrane Database Syst Rev. 2016 Oct 13;10(10):CD005231. doi: 10.1002/14651858.CD005231.pub3.
9
用于成人慢性神经性疼痛的大麻类药物。
Cochrane Database Syst Rev. 2018 Mar 7;3(3):CD012182. doi: 10.1002/14651858.CD012182.pub2.
10
老年人髋关节囊外骨折的手术干预:一项网络荟萃分析。
Cochrane Database Syst Rev. 2022 Feb 10;2(2):CD013405. doi: 10.1002/14651858.CD013405.pub2.

引用本文的文献

本文引用的文献

2
4
大麻使用对阿片类激动剂治疗结果的影响差异:来自 OPTIMA 研究的探索性分析。
J Subst Use Addict Treat. 2023 Jun;149:209031. doi: 10.1016/j.josat.2023.209031. Epub 2023 Mar 30.
5
临床实践指南:大麻和大麻素类药物在慢性疼痛及共病管理中的应用。
Cannabis Cannabinoid Res. 2024 Apr;9(2):669-687. doi: 10.1089/can.2021.0156. Epub 2023 Mar 27.
6
澳大利亚大麻合法化时期前后大麻使用意向的趋势:一项年龄-时期-队列模型研究。
Drug Alcohol Rev. 2023 Feb;42(2):337-345. doi: 10.1111/dar.13578. Epub 2022 Nov 29.
7
从种植者到患者:多方利益相关者对在澳大利亚使用和获取药用大麻的看法。
PLoS One. 2022 Nov 11;17(11):e0277355. doi: 10.1371/journal.pone.0277355. eCollection 2022.
8
医用大麻的兴起与崛起,现在如何?澳大利亚 2017-2022 年医用大麻的处方情况。
Int J Environ Res Public Health. 2022 Aug 10;19(16):9853. doi: 10.3390/ijerph19169853.
10
美国对大麻合法化态度趋势的系统综述
Subst Use Misuse. 2022;57(7):1052-1061. doi: 10.1080/10826084.2022.2063893. Epub 2022 Apr 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验